Genome-wide Association Study Identifies a Psoriasis Susceptibility Locus at TRAF3IP2

Overview

Journal Nat Genet

Specialty Genetics

Date 2010 Oct 19

PMID 20953188

Citations 175

Authors

Eva Ellinghaus

David Ellinghaus

Philip E Stuart

Rajan P Nair

Sophie Debrus

John V Raelson

Majid Belouchi

Helene Fournier

Claudia Reinhard

Jun Ding

Yun Li

Trilokraj Tejasvi

Johann Gudjonsson

Stefan W Stoll

John J Voorhees

Sylviane Lambert

Stephan Weidinger

Bernadette Eberlein

Manfred Kunz

Proton Rahman

Dafna D Gladman

Christian Gieger

H Erich Wichmann

Tom H Karlsen

Gabriele Mayr

Mario Albrecht

Dieter Kabelitz

Ulrich Mrowietz

Goncalo R Abecasis

James T Elder

Stefan Schreiber

Michael Weichenthal

Andre Franke

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a multifactorial skin disease characterized by epidermal hyperproliferation and chronic inflammation, the most common form of which is psoriasis vulgaris (PsV). We present a genome-wide association analysis of 2,339,118 SNPs in 472 PsV cases and 1,146 controls from Germany, with follow-up of the 147 most significant SNPs in 2,746 PsV cases and 4,140 controls from three independent replication panels. We identified an association at TRAF3IP2 on 6q21 and genotyped two SNPs at this locus in two additional replication panels (the combined discovery and replication panels consisted of 6,487 cases and 8,037 controls; combined P = 2.36 × 10⁻¹⁰ for rs13210247 and combined P = 1.24 × 10⁻¹⁶ for rs33980500). About 15% of psoriasis cases develop psoriatic arthritis (PsA). A stratified analysis of our datasets including only PsA cases (1,922 cases compared to 8,037 controls, P = 4.57 × 10⁻¹² for rs33980500) suggested that TRAF3IP2 represents a shared susceptibility for PsV and PsA. TRAF3IP2 encodes a protein involved in IL-17 signaling and which interacts with members of the Rel/NF-κB transcription factor family.

Citing Articles

GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets.

Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J Nat Commun. 2025; 16(1):2051.

PMID: 40021644 PMC: 11871359. DOI: 10.1038/s41467-025-56719-8.

Multi-ancestry genome-wide meta-analysis with 472,819 individuals identifies 32 novel risk loci for psoriasis.

Zhang M, Su W, Deng J, Zhai B, Zhu G, Gao R J Transl Med. 2025; 23(1):133.

PMID: 39885523 PMC: 11783861. DOI: 10.1186/s12967-024-06015-8.

Causal effect of psoriasis on aortic valve stenosis: a two-sample Mendelian randomization study.

Jiang K, Wang Y, Liu Y, Xu Y, Huang F, Chen M J Geriatr Cardiol. 2024; 21(9):865-873.

PMID: 39483265 PMC: 11522712. DOI: 10.26599/1671-5411.2024.09.002.

Significant Correlation Between Cutaneous Abundance of Streptococcus and Psoriasis Severity in Patients with FBXL19 Gene Variants.

Assarsson M, Soderman J, Seifert O Acta Derm Venereol. 2024; 104:adv34892.

PMID: 38898675 PMC: 11210493. DOI: 10.2340/actadv.v104.34892.

Genetic underpinnings of the psoriatic spectrum.

Huffmeier U, Klima J, Hayatu M Med Genet. 2024; 35(1):46-54.

PMID: 38835412 PMC: 10842586. DOI: 10.1515/medgen-2023-2005.

References

Zaba L, Suarez-Farinas M, Fuentes-Duculan J, Nograles K, Guttman-Yassky E, Cardinale I . Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009; 124(5):1022-10.e1-395. PMC: 2852188. DOI: 10.1016/j.jaci.2009.08.046. View

Qian Y, Liu C, Hartupee J, Altuntas C, Gulen M, Jane-Wit D . The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol. 2007; 8(3):247-56. DOI: 10.1038/ni1439. View

Stoll S, Johnson J, Li Y, Rittie L, Elder J . Amphiregulin carboxy-terminal domain is required for autocrine keratinocyte growth. J Invest Dermatol. 2010; 130(8):2031-40. PMC: 3072808. DOI: 10.1038/jid.2010.98. View

Sherry S, Ward M, Kholodov M, Baker J, Phan L, Smigielski E . dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2000; 29(1):308-11. PMC: 29783. DOI: 10.1093/nar/29.1.308. View

Bhalerao J, Bowcock A . The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet. 1998; 7(10):1537-45. DOI: 10.1093/hmg/7.10.1537. View

Zhang X, Yan K, Wang Z, Yang S, Zhang G, Fan X . Polymorphisms in interleukin-15 gene on chromosome 4q31.2 are associated with psoriasis vulgaris in Chinese population. J Invest Dermatol. 2007; 127(11):2544-51. DOI: 10.1038/sj.jid.5700896. View

Lowes M, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba L, Haider A . Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008; 128(5):1207-11. DOI: 10.1038/sj.jid.5701213. View

Qian Y, Qin J, Cui G, Naramura M, Snow E, Ware C . Act1, a negative regulator in CD40- and BAFF-mediated B cell survival. Immunity. 2004; 21(4):575-87. DOI: 10.1016/j.immuni.2004.09.001. View

Stoll S, Johnson J, Bhasin A, Johnston A, Gudjonsson J, Rittie L . Metalloproteinase-mediated, context-dependent function of amphiregulin and HB-EGF in human keratinocytes and skin. J Invest Dermatol. 2009; 130(1):295-304. PMC: 2795126. DOI: 10.1038/jid.2009.211. View

10.

Li Y, Willer C, Sanna S, Abecasis G . Genotype imputation. Annu Rev Genomics Hum Genet. 2009; 10:387-406. PMC: 2925172. DOI: 10.1146/annurev.genom.9.081307.164242. View

11.

Bowcock A, Barker J . Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol. 2003; 49(2 Suppl):S51-6. DOI: 10.1016/s0190-9622(03)01135-6. View

12.

Gelfand J, Gladman D, Mease P, Smith N, Margolis D, Nijsten T . Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005; 53(4):573. DOI: 10.1016/j.jaad.2005.03.046. View

13.

Tsunemi Y, Saeki H, Nakamura K, Sekiya T, Hirai K, Fujita H . Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci. 2002; 30(2):161-6. DOI: 10.1016/s0923-1811(02)00072-5. View

14.

Gottlieb A . Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov. 2005; 4(1):19-34. DOI: 10.1038/nrd1607. View

15.

Hunter C . Act1-ivating IL-17 inflammation. Nat Immunol. 2007; 8(3):232-4. DOI: 10.1038/ni0307-232. View

16.

Nair R, Callis Duffin K, Helms C, Ding J, Stuart P, Goldgar D . Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009; 41(2):199-204. PMC: 2745122. DOI: 10.1038/ng.311. View

17.

de Cid R, Riveira-Munoz E, Zeeuwen P, Robarge J, Liao W, Dannhauser E . Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet. 2009; 41(2):211-5. PMC: 3128734. DOI: 10.1038/ng.313. View

18.

Griffiths C, Barker J . Pathogenesis and clinical features of psoriasis. Lancet. 2007; 370(9583):263-271. DOI: 10.1016/S0140-6736(07)61128-3. View

19.

Darnay B, Ni J, Moore P, Aggarwal B . Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem. 1999; 274(12):7724-31. DOI: 10.1074/jbc.274.12.7724. View

20.

Capon F, Di Meglio P, Szaub J, Prescott N, Dunster C, Baumber L . Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet. 2007; 122(2):201-6. DOI: 10.1007/s00439-007-0397-0. View